Publication Name	World Journal of Diabetes
Manuscript ID	24895
Country	India

Received	2016-02-14 10:02
Peer-Review Started	2016-02-16 14:46
To Make the First Decision	2016-03-23 10:37
Return for Revision	2016-03-25 17:16
Revised	2016-05-16 18:01
Second Decision	2016-07-28 14:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-08-10 11:52
Articles in Press	2016-08-10 11:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-09-27 15:49
Publish the Manuscript Online	2016-10-11 11:41

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Manuscript Source	Invited Manuscript
All Author List	Sanjay Chatterjee, Samit Ghosal and Saurav Chatterjee
Funding Agency and Grant Number
Corresponding Author	Sanjay Chatterjee, MD, Consultant Diabetologist, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata 700054, India. sanjay_doc@yahoo.co.in
Key Words	Metabolic syndrome; Diabetes; Glucagon-like peptide-1 receptor agonists; Lipids; Body weight; Microalbuminuria
Core Tip	The incidence of metabolic syndrome (MetS) is on the rise globally. This will have a negative impact on cardiovascular outcome. Whereas most of the anti-hyperglycemic agents have neutral or negative effects on components of MetS, glucagon-like peptide-1 receptor agonists drugs favorably address all components of MetS. By doing so, they may have a cardio protective role. We have reviewed recent literature to give an updated account on the topic. Results from recently concluded clinical trials suggest that some of the molecules in this class may have favor-able effects on cardiovascular outcome.
Publish Date	2016-10-11 11:41
Citation	Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J Diabetes 2016; 7(18): 441-448
URL	http://www.wjgnet.com/1948-9358/full/v7/i18/441.htm
DOI	http://dx.doi.org/10.4239/wjd.v7.i18.441

Full Article (PDF)	WJD-7-441.pdf
Full Article (Word)	WJD-7-441.doc
Manuscript File	24895-Review.doc
Answering Reviewers	24895-Answering reviewers.pdf
Audio Core Tip	24895-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	24895-Conflict-of-interest statement.pdf
Copyright License Agreement	24895-Copyright assignment.pdf
Peer-review Report	24895-Peer-review(s).pdf
Scientific Misconduct Check	24895-Scientific misconduct check.pdf
Scientific Editor Work List	24895-Scientific editor work list.pdf